Team:Brown/Project Implications



= Safety Issues = This project raises safety issues due to the use of Staphylococcus epidermidis for producing and secreting the histamine binding protein, EV131. Although S. epidermidis is one of the more benign species of Staphylococcus, it can form infectious biofilms that are impervious to antibiotic treatment if its cell density becomes too great. This could pose a grave risk to researchers involved and the public for whom Allergene aims to serve.

This change in S. epidermidis phenotype is accomplished by the S. epidermidis agr operon, which upregulates pathogenicity genes in response to a quorum. We reasoned that we could incorporate a safety mechanism into our bacteria by putting a death gene under the regulation of the agr promoter. This way, whenever the bacteria would reach a high enough density to become dangerous, they would simply begin to die until they reach a safer, lower density. In order to first test that our cassette works, we ligated the agr promoter upstream of GFP, so that whenever the cells reached a quorum, they would fluoresce green. Later, the GFP would be switched out for a CCDb, a death gene.

= Institutional Biosafety Regulation = Any member of the Brown University faculty, staff, post-doctoral, and student bodies who plans to initiate research involving human subjects must submit a protocol for review and approval by the Institutional Review Board (IRB) prior to beginning the project. The Research Protections Office (RPO) staff provides administrative support to researchers who are preparing protocols for presentation to the IRB.

The Institutional Animal Care & Use Committee (IACUC) ensures the health, well-being, and humane use of animals used in research at Brown, following the regulations and guidance of the U.S. Department of Agriculture and the Department of Health and Human Services. IACUC staff is available to answer administrative questions, and campus veterinarians can provide consultation and assistance on animal care and questions regarding experimental protocols. For our project, however, we have not yet proceeded to preclinical testing stage. For in vivo research, the Office of Environmental Health and Safety (EHS) at Brown provides compliance tools to optimize laboratory and facility conditions across research projects, from safe handling of potentially hazardous materials to biosafety training. EHS also has created guidelines to describe its emergency response system, environmental strategies, and lab equipment rules.

We presented and proposed our project to the Office of Environmental Health and Safety at Brown University. Initially, we ran into concerns about the Biosafety Level 2 classification of the proposed bacteria, Staphylococcus aureus, that we planned to use for expression of the histamine binding protein. With further consideration of the biohazard implications of S. aureus, we decided instead to utilize Staphylococcus epidermidis for the expression of the histamine binding protein. Using S. epidermidis provided us with two major benefits:

 1) S. epidermidis is endogenous to the nasal flora and thus, very well-suited for accomplishing the eventual goal of our project. 

 2) S. epidermidis is Biosafety Level 1, eliminating the fears that would have been associated with a Biosafety Level 2 bacterium. 

= Ethics, Ethics, Ethics = An important concern regarding many iGEM projects, including ours, is the introduction of genetically engineered organisms into a human body. In particular, for our project we are engineering a strain of a bacterium that normally lives in a human environment without any problems, by introducing an immune response suppressant function to that organism. This raises some potential ethical problems. For example, what if the engineered bacteria an allergy sufferer takes to relieve their symptoms causes an infection?

Regarding the potential concern that synthetic biologists are "playing God", with potentially harmful effects, we on the Brown team feel that any technology can be used for "good" or "bad" purposes. Just as nuclear reactions can be used for generating electricity or destroying cities, so too can synthetic biology be used for both positive and negative ends. The same techniques that allow us to genetically engineer Staphylococcus epidermidis for the "good" purpose of treating allergies could allow one to create a "bad" super multi-antibiotic resistant strain of Staphylococcus aureus (a closely related species to Staphylococcus epidermidis that is highly pathogenic, and responsible for increasing numbers of fatal infections). Unlike nuclear energy, however, this technology is so cheap and relatively easy to use that it is accessible even to high school and college students. It would be extremely difficult to create a central body that controls what end people put synthetic biological technology towards. As such, we think that it is the responsibility of everyone in the synthetic biological community to use this technology only for "good" ends, and to think about the consequences of our manipulations. We on the Brown team have tried our best to be conscious of these implications, and to engineer our machine accordingly.

